Adrixetinib - Qurient Therapeutics
Alternative Names: Axl/Mer/CSF1R triple Inhibitor; Q-702Latest Information Update: 09 Dec 2024
Price :
$50 *
At a glance
- Originator The Lead Discovery Center; The Max Planck Institute of Biochemistry; Vichem Chemie
- Developer Merck & Co; Qurient Co
- Class Antineoplastics; Small molecules
- Mechanism of Action Axl receptor tyrosine kinase inhibitors; Macrophage colony-stimulating factor receptor antagonists; Proto-oncogene protein c-mer inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Solid tumours
- Phase I Acute myeloid leukaemia; Haematological malignancies
- No development reported Non-small cell lung cancer
Most Recent Events
- 04 Dec 2024 Mayo Clinic plans a phase I trial for Haematological malignancies (Second-line therapy or greater) in USA (PO) (NCT06712810)
- 25 Oct 2024 Phase-I clinical trials in Acute myeloid leukaemia (Combination therapy, Second-line therapy or greater) in USA (PO) (NCT06445907)
- 25 Oct 2024 Phase-I clinical trials in Acute myeloid leukaemia (Monotherapy, Second-line therapy or greater) in USA (PO) (NCT06445907)